KILITCH DRUGS (INDIA) LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 363.4 INR | +1.34% |
|
+2.45% | -2.25% |
| Sales 2022 | 1.14B 13.7M 1.09B | Sales 2023 | 1.4B 16.74M 1.34B | Capitalization | 2.17B 26.07M 2.08B |
|---|---|---|---|---|---|
| Net income 2022 | 73M 875K 69.82M | Net income 2023 | 104M 1.25M 99.47M | EV / Sales 2022 | 1.96 x |
| Net cash position 2022 | 369M 4.42M 353M | Net cash position 2023 | 370M 4.43M 354M | EV / Sales 2023 | 1.29 x |
| P/E ratio 2022 |
35.5
x | P/E ratio 2023 |
20.8
x | Employees | 153 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 23.7% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.34% | ||
| 1 week | +2.45% | ||
| Current month | -6.78% | ||
| 1 month | -4.53% | ||
| 3 months | -17.09% | ||
| 6 months | +40.31% | ||
| Current year | -2.25% |
1 week
340.80
367.70
1 month
336.20393.90
Current year
321.50469.85
1 year
157.00469.85
3 years
100.60469.85
5 years
63.00469.85
10 years
19.80469.85
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 70 | 11/05/92 | |
| Director of Finance/CFO | 40 | 28/02/21 | |
Pushpa Nyoupane
CMP | Compliance Officer | - | 04/05/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 70 | 11/05/92 | |
| Director/Board Member | 48 | 28/09/07 | |
| Director/Board Member | 58 | 31/03/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 363.4 | +1.34% | 89 |
| 26/04/24 | 358.6 | +2.15% | 3,022 |
| 25/04/24 | 351 | +0.41% | 702 |
| 24/04/24 | 349.6 | +0.16% | 481 |
| 23/04/24 | 349 | -1.59% | 826 |
Delayed Quote Bombay S.E., April 29, 2024 at 05:03 am
More quotes
Kilitch Drugs (India) Limited is an India-based pharmaceutical manufacturing company. The Company is engaged in developing, manufacturing and marketing a range of pharmaceutical formulations. The Companyâs products include Parenteral and Nasal Products, Oral, Effervescent, Nutritional Products, Medical Devices, and Cosmetics and Herbal Products. Its Parenteral and Nasal Products has a range of products that help in gastroenterology, anti-inflammatory, anti-malaria, diagnostic, uterine stimulants, veterinary and other areas in the form of ampoules and vials. Its range of oral formulations includes tablets, capsules, dry syrups and oral powders. It provides a range of cosmetics ranging from oil, lotion, liquid to cream and paste in the skin care, personal care and hair care categories. Its herbal products are useful for sore throat, prostate problems, and can be used as supplements for diabetes, obesity, libido and others. Its medical devices offer a C-Seal brand.
Sector
Pharmaceuticals
Calendar
23/05/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -2.25% | 69.15M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- KILITCH Stock
